B-RAF and its novel negative regulator reticulocalbin 1 (RCN1) modulates cardiomyocyte hypertrophyNadine Kramann(University of Göttingen), Tim Seidler(Temple College)Cardiovascular ResearchFebruary 2, 201410.1093/cvr/cvu024Cited by 19SaveCiteExport RISWatch citationsRelated PapersMavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial|The Lancet|2020|1.2kMavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy|Circulation|2020|234